IL247773A0 - Pyridine-2-carboxamides 5,6-dimuters as cannabinoid receptor antagonists - Google Patents
Pyridine-2-carboxamides 5,6-dimuters as cannabinoid receptor antagonistsInfo
- Publication number
- IL247773A0 IL247773A0 IL247773A IL24777316A IL247773A0 IL 247773 A0 IL247773 A0 IL 247773A0 IL 247773 A IL247773 A IL 247773A IL 24777316 A IL24777316 A IL 24777316A IL 247773 A0 IL247773 A0 IL 247773A0
- Authority
- IL
- Israel
- Prior art keywords
- carboxamides
- receptor agonists
- cannabinoid receptor
- disubstituted pyridine
- disubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14163554 | 2014-04-04 | ||
PCT/EP2015/057144 WO2015150438A1 (fr) | 2014-04-04 | 2015-04-01 | Pyridine-2-carboxamides bisubstitués en 5,6 servant d'agonistes du récepteur cannabinoïde |
Publications (1)
Publication Number | Publication Date |
---|---|
IL247773A0 true IL247773A0 (en) | 2016-11-30 |
Family
ID=50424142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL247773A IL247773A0 (en) | 2014-04-04 | 2016-09-12 | Pyridine-2-carboxamides 5,6-dimuters as cannabinoid receptor antagonists |
Country Status (18)
Country | Link |
---|---|
US (2) | US20160376237A1 (fr) |
EP (1) | EP3126349B1 (fr) |
JP (1) | JP6353072B2 (fr) |
KR (2) | KR20160132495A (fr) |
CN (2) | CN106458984A (fr) |
AR (1) | AR099932A1 (fr) |
AU (1) | AU2015239537B2 (fr) |
CA (1) | CA2944256A1 (fr) |
CL (1) | CL2016002389A1 (fr) |
CR (1) | CR20160459A (fr) |
EA (1) | EA030032B1 (fr) |
IL (1) | IL247773A0 (fr) |
MX (1) | MX2016012690A (fr) |
PE (1) | PE20161407A1 (fr) |
PH (1) | PH12016501849A1 (fr) |
SG (1) | SG11201608246VA (fr) |
TW (1) | TW201625538A (fr) |
WO (1) | WO2015150438A1 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA027569B1 (ru) | 2013-03-26 | 2017-08-31 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина |
CN106132953B (zh) | 2014-04-04 | 2019-03-22 | H.隆德贝克有限公司 | 作为pde1抑制剂的卤化的喹唑啉-thf-胺 |
MY195889A (en) * | 2015-12-09 | 2023-02-27 | Hoffmann La Roche | Phenyl Derivatives as Cannabinoid Receptor 2 Agonists |
GB201703282D0 (en) * | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
JP7300398B2 (ja) | 2017-06-20 | 2023-06-29 | エフ. ホフマン-ラ ロシュ アーゲー | ピリジン誘導体 |
EP3995155A1 (fr) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Ligands radiomarqués du récepteur cannabinoïde 2 |
EP3814328A1 (fr) * | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Nouveaux composés de pyridine et de pyrazine substitués par azétidine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
MA53002A (fr) * | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
CN112074513B (zh) * | 2018-06-27 | 2024-06-14 | 豪夫迈·罗氏有限公司 | 作为优先大麻素2激动剂的吡啶和吡嗪衍生物 |
WO2023145372A1 (fr) * | 2022-01-28 | 2023-08-03 | 日本曹達株式会社 | Procédé de production d'un composé amide |
CN115160306B (zh) * | 2022-08-04 | 2024-03-26 | 上海皓鸿生物医药科技有限公司 | 一种特力利汀中间体的合成方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101114704B1 (ko) * | 2006-10-04 | 2012-03-14 | 에프. 호프만-라 로슈 아게 | Cb2 수용체 조절제로서 피라진-2-카복스아마이드 유도체 |
WO2012031817A1 (fr) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Détermination des niveaux de protéine abca1 dans des cellules |
US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
US9303012B2 (en) * | 2012-12-07 | 2016-04-05 | Hoffman-La Roche Inc. | Pyridine-2-amides useful as CB2 agonists |
HUE036911T2 (hu) * | 2012-12-07 | 2018-08-28 | Hoffmann La Roche | Új piridin származékok |
-
2015
- 2015-04-01 CN CN201580016783.5A patent/CN106458984A/zh active Pending
- 2015-04-01 WO PCT/EP2015/057144 patent/WO2015150438A1/fr active Application Filing
- 2015-04-01 PE PE2016001892A patent/PE20161407A1/es unknown
- 2015-04-01 KR KR1020167030794A patent/KR20160132495A/ko not_active Application Discontinuation
- 2015-04-01 MX MX2016012690A patent/MX2016012690A/es unknown
- 2015-04-01 SG SG11201608246VA patent/SG11201608246VA/en unknown
- 2015-04-01 CA CA2944256A patent/CA2944256A1/fr not_active Abandoned
- 2015-04-01 AU AU2015239537A patent/AU2015239537B2/en not_active Expired - Fee Related
- 2015-04-01 EP EP15712968.5A patent/EP3126349B1/fr active Active
- 2015-04-01 EA EA201691982A patent/EA030032B1/ru not_active IP Right Cessation
- 2015-04-01 AR ARP150100984A patent/AR099932A1/es unknown
- 2015-04-01 CN CN202010029759.8A patent/CN111170938A/zh active Pending
- 2015-04-01 JP JP2016560828A patent/JP6353072B2/ja active Active
- 2015-04-01 CR CR20160459A patent/CR20160459A/es unknown
- 2015-04-01 KR KR1020187016509A patent/KR20180072827A/ko not_active Application Discontinuation
- 2015-04-02 TW TW104111028A patent/TW201625538A/zh unknown
-
2016
- 2016-09-09 US US15/260,819 patent/US20160376237A1/en not_active Abandoned
- 2016-09-12 IL IL247773A patent/IL247773A0/en unknown
- 2016-09-21 PH PH12016501849A patent/PH12016501849A1/en unknown
- 2016-09-22 CL CL2016002389A patent/CL2016002389A1/es unknown
-
2018
- 2018-07-20 US US16/041,641 patent/US20180327360A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20180072827A (ko) | 2018-06-29 |
PE20161407A1 (es) | 2016-12-28 |
AU2015239537B2 (en) | 2019-04-04 |
CN106458984A (zh) | 2017-02-22 |
WO2015150438A1 (fr) | 2015-10-08 |
CA2944256A1 (fr) | 2015-10-08 |
AR099932A1 (es) | 2016-08-31 |
US20160376237A1 (en) | 2016-12-29 |
SG11201608246VA (en) | 2016-10-28 |
CL2016002389A1 (es) | 2017-03-17 |
EP3126349A1 (fr) | 2017-02-08 |
EA201691982A1 (ru) | 2017-01-30 |
PH12016501849A1 (en) | 2016-12-19 |
US20180327360A1 (en) | 2018-11-15 |
EA030032B1 (ru) | 2018-06-29 |
JP2017509688A (ja) | 2017-04-06 |
MX2016012690A (es) | 2017-04-27 |
CN111170938A (zh) | 2020-05-19 |
KR20160132495A (ko) | 2016-11-18 |
JP6353072B2 (ja) | 2018-07-04 |
EP3126349B1 (fr) | 2019-06-26 |
TW201625538A (zh) | 2016-07-16 |
AU2015239537A1 (en) | 2016-11-17 |
CR20160459A (es) | 2016-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261629B1 (en) | Cannobinoid compounds are rich in terpenes | |
ZA201802451B (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
ZA201806356B (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
IL247773A0 (en) | Pyridine-2-carboxamides 5,6-dimuters as cannabinoid receptor antagonists | |
HK1255163A1 (zh) | 作為apj受體激動劑的雜芳基羥基嘧啶酮 | |
IL246373B (en) | Pyrimidinyloxy benzene derivatives as herbicides | |
PL3368014T3 (pl) | Nowe preparaty kannabinoidów | |
PL3023431T3 (pl) | Stężone kompozycje ramnolipidowe o niskiej lepkości | |
HRP20190107T1 (hr) | Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens | |
EP3186225A4 (fr) | Modulateurs du récepteur cannabinoïde de type 1 | |
IL247817A0 (en) | Pyridine–2–amides are useful as cb2 agonists | |
HK1257166A1 (zh) | 作為大麻素受體2激動劑的苯基衍生物 | |
SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
HK1254800A1 (zh) | 2,3,4,5-四氫吡啶-6-胺衍生物 | |
IL247881B (en) | Cannabinoid compounds are protein bound | |
PL3233768T3 (pl) | Synteza 1,3-butadienu | |
GB201420970D0 (en) | eGURE, egure, Egure | |
GB201413121D0 (en) | The E.M.S As Pripulsian | |
SG10201402964RA (en) | Dehydration of 2,3-butanediole | |
GB201400595D0 (en) | The E.M.S as propotsion |